3 completed, 1 terminated, 1 unknown. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Unknown 1 |
| Phase 1 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow azaspirane: new trials by email Literature Review of azaspirane trials Research Report on azaspirane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma Atiprimod - Neuroendocrine Carcinoma | Phase 2 | Completed | Callisto Pharmaceuticals | 10 | 2007-11-01 | 2011-08-31 |
| Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Atiprimod - Neuroendocrine Carcinoma | Phase 2 | Completed | Callisto Pharmaceuticals | 55 | 2006-10-01 | 2007-12-21 |
| Study of Atiprimod Treatment for Patients With Advanced Cancer Atiprimod - Advanced Cancer | Phase 1 | Terminated | M.D. Anderson Cancer Center | 28 | 2005-03-01 | 2012-02-15 |
| An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer Atiprimod - Advanced Cancer | Phase 1 / Phase 2 | Unknown | Callisto Pharmaceuticals | 61 | 2005-03-01 | 2006-12-05 |
| Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma Atiprimod - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Callisto Pharmaceuticals | 30 | 2004-05-01 | 2007-12-21 |
Carcinoma, Neuroendocrine (2) · Carcinoid Tumor (1) · Carcinoma (1) · Multiple Myeloma (1) · Neoplasms (1) · Recurrence (1)
Callisto Pharmaceuticals (4) · M.D. Anderson Cancer Center (1)
United States (5)
Donald Picker, PhD (1) · Gary Jacob, Ph.D. (1) · Gary Jacob, PhD (1) · Gary S Jacob, PhD (1) · Razelle Kurzrock, MD (1)